In meningitis scare, charges firm misled U.S. regulators

NASHVILLE, Tennessee (Reuters) – The deadly meningitis outbreak that has claimed a dozen lives is prompting calls for increased oversight of the nation’s custom-made pharmaceutical industry, amid charges that the company at the center of the scare may have misled U.S. regulators. On Wednesday, Idaho became the 11th state to report a case of the rare illness, which has been linked to tainted steroids produced by a specialty pharmacy in Massachusetts. The U.S. …